SLC30A8 and type 1 diabetes mellitus: The similar frequencies of Abs recognizing MAP3865c and ZnT8 homologous regions among T1D patients (65.4–68.0% and 51.6–55.6%, respectively; Fig. 5) suggest that Abs targeting these epitopes could be cross-reactive.